Researchers in Germany claim to have made significant progress in the development of a nasal Covid-19 vaccine that can effectively shut down the virus's infection in the nose and throat. In experiments conducted on hamsters, two doses of the live but weakened vaccine successfully blocked the virus from replicating itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness.
The novel approach uses a weakened form of the coronavirus that causes Covid-19, which is then used to prime the immune system. This method has been studied for decades, dating back to the 1870s when scientists developed vaccines against anthrax and rabies using similar techniques.
According to the researchers, the nasal vaccine offers several advantages over existing Covid-19 vaccines. It can be administered through the nose, making it easier to target the upper airways where the virus typically enters the body. Additionally, this approach may provide better protection against new variants of the virus that have emerged in recent times.
In the hamster studies, two doses of the live but weakened nasal vaccine created a stronger immune response compared to other vaccines tested, including mRNA-based and adenovirus-delivered options. The researchers believe that the vaccine's effectiveness is due to its ability to mimic natural infection closely, allowing it to generate immunity against a wider range of targets.
However, the development of this vaccine still faces several challenges before it can be approved for human use. The researchers are currently working on phase I clinical trials with the help of a Swiss company called RocketVax. While other nasal vaccines have reached late-stage testing in humans, some experts caution that more work is needed to fully understand their effectiveness.
One concern is that respiratory infections have proven to be tough targets for inhaled vaccines, and it remains to be seen whether this approach will be effective in humans. Nonetheless, the progress made by German researchers offers hope for a new type of Covid-19 vaccine that could provide better protection against the virus.
The novel approach uses a weakened form of the coronavirus that causes Covid-19, which is then used to prime the immune system. This method has been studied for decades, dating back to the 1870s when scientists developed vaccines against anthrax and rabies using similar techniques.
According to the researchers, the nasal vaccine offers several advantages over existing Covid-19 vaccines. It can be administered through the nose, making it easier to target the upper airways where the virus typically enters the body. Additionally, this approach may provide better protection against new variants of the virus that have emerged in recent times.
In the hamster studies, two doses of the live but weakened nasal vaccine created a stronger immune response compared to other vaccines tested, including mRNA-based and adenovirus-delivered options. The researchers believe that the vaccine's effectiveness is due to its ability to mimic natural infection closely, allowing it to generate immunity against a wider range of targets.
However, the development of this vaccine still faces several challenges before it can be approved for human use. The researchers are currently working on phase I clinical trials with the help of a Swiss company called RocketVax. While other nasal vaccines have reached late-stage testing in humans, some experts caution that more work is needed to fully understand their effectiveness.
One concern is that respiratory infections have proven to be tough targets for inhaled vaccines, and it remains to be seen whether this approach will be effective in humans. Nonetheless, the progress made by German researchers offers hope for a new type of Covid-19 vaccine that could provide better protection against the virus.